MOLOGNI LUCA
- U08, Piano: 4, Stanza: LABORATORIO 4.10
- U08, Piano: 4, Stanza: 4043
Pubblicazioni
Villa, M., Malighetti, F., Sala, E., Sharma, G., Arosio, G., Gemelli, M., et al. (2024). New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ PRECISION ONCOLOGY, 8(1) [10.1038/s41698-024-00498-w]. Dettaglio
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Dettaglio
Fontana, D., Crespiatico, I., Crippa, V., Malighetti, F., Villa, M., Angaroni, F., et al. (2023). Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients. NATURE COMMUNICATIONS, 14(1) [10.1038/s41467-023-41670-3]. Dettaglio
Mastini, C., Campisi, M., Patrucco, E., Mura, G., Ferreira, A., Costa, C., et al. (2023). Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 15(702), 1-17 [10.1126/scitranslmed.abo3826]. Dettaglio
Malighetti, F., Arosio, G., Manfroni, C., Mauri, M., Villa, M., Manghisi, B., et al. (2023). DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients. HEMASPHERE, 7(3) [10.1097/HS9.0000000000000852]. Dettaglio